BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 103 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2014. The put-call ratio across all filers is 0.92 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $611,000 | +44.8% | 60,000 | +6.0% | 0.02% | +57.1% |
Q4 2020 | $422,000 | +62.3% | 56,600 | -25.1% | 0.01% | +55.6% |
Q3 2020 | $260,000 | -31.9% | 75,600 | -5.7% | 0.01% | -10.0% |
Q2 2020 | $382,000 | +126.0% | 80,200 | -5.3% | 0.01% | +100.0% |
Q1 2020 | $169,000 | -70.5% | 84,700 | -43.9% | 0.01% | -61.5% |
Q2 2019 | $572,000 | -70.1% | 150,998 | -35.7% | 0.01% | -66.7% |
Q1 2019 | $1,913,000 | +2.5% | 234,898 | +1.6% | 0.04% | -2.5% |
Q4 2018 | $1,866,000 | +1.0% | 231,198 | -4.5% | 0.04% | +21.2% |
Q3 2018 | $1,847,000 | +29.8% | 241,998 | -2.5% | 0.03% | +32.0% |
Q2 2018 | $1,423,000 | +1.0% | 248,198 | -15.9% | 0.02% | +4.2% |
Q1 2018 | $1,409,000 | +3.4% | 295,166 | +6.3% | 0.02% | +4.3% |
Q4 2017 | $1,363,000 | +247.7% | 277,567 | +271.6% | 0.02% | +155.6% |
Q3 2017 | $392,000 | +166.7% | 74,700 | +398.0% | 0.01% | +80.0% |
Q3 2014 | $147,000 | +104.2% | 15,000 | +51.5% | 0.01% | +66.7% |
Q3 2013 | $72,000 | – | 9,900 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |